Related Experiment Video
Updated: Jul 16, 2026

A Rat Tibial Growth Plate Injury Model to Characterize Repair Mechanisms and Evaluate Growth Plate Regeneration Strategies
Published on: July 4, 2017
Rapamycin retards growth and causes marked alterations in the growth plate of young rats
Oscar Alvarez-Garcia1, Eduardo Carbajo-Pérez, Enrique Garcia
1Universidad de Oviedo, Oviedo, Spain.
Abstract:
Rapamycin is a potent immunosuppressant with antitumoral properties widely used in the field of renal transplantation. To test the hypothesis that the antiproliferative and antiangiogenic activity of rapamycin interferes with the normal structure and function of growth plate and impairs longitudinal growth, 4-week-old male rats (n = 10/group) receiving 2 mg/kg per day of intraperitoneal rapamycin (RAPA) or vehicle (C) for 14 days were compared. Rapamycin markedly decreased bone longitudinal growth rate (94 +/- 3 vs. 182 +/- 3 microm/day), body weight gain (60.2 +/- 1.4 vs. 113.6 +/- 1.9 g), food intake (227.8 +/- 2.6 vs. 287.5 +/- 3.4 g), and food efficiency (0.26 +/- 0.00 vs. 0.40 +/- 0.01 g/g). Signs of altered cartilage formation such as reduced chondrocyte proliferation (bromodeoxiuridine-labeled cells 32.9 +/- 1.4 vs. 45.2 +/- 1.1%), disturbed maturation and hypertrophy (height of terminal chondrocytes 26 +/- 0 vs. 29 +/- 0 microm), and decreased cartilage resorption (18.7 +/- 0.5 vs. 31.0 +/- 0.8 tartrate-resistant phosphatase alkaline reactive cells per 100 terminal chondrocytes), together with morphological evidence of altered vascular invasion, were seen in the growth plate of RAPA animals. This study indicates that rapamycin can severely impair body growth in fast-growing rats and distort growth-plate structure and dynamics. These undesirable effects must be kept in mind when rapamycin is administered to children.
Insights
Rapamycin significantly hinders bone growth and alters growth plate structure in young rats. These findings highlight potential risks for children receiving this immunosuppressant medication.
Area of Science:
- Pharmacology
- Pediatric Endocrinology
- Orthopedics
Background:
- Rapamycin is an immunosuppressant used in renal transplantation with known antitumoral effects.
- Its antiproliferative and antiangiogenic properties raise concerns about potential impacts on growth.
- The effect of rapamycin on the pediatric growth plate is not well understood.
Purpose of the Study:
- To investigate the effects of rapamycin on longitudinal bone growth and growth plate dynamics.
- To test the hypothesis that rapamycin interferes with normal growth plate structure and function.
- To evaluate rapamycin's impact on body weight gain, food intake, and food efficiency.
Main Methods:
- 4-week-old male rats received daily intraperitoneal injections of rapamycin (2 mg/kg) or vehicle for 14 days.
- Longitudinal bone growth rate, body weight gain, food intake, and food efficiency were measured.
- Growth plate structure was assessed by examining chondrocyte proliferation, maturation, hypertrophy, cartilage resorption, and vascular invasion.
Main Results:
- Rapamycin significantly reduced bone longitudinal growth rate by approximately 50%.
- Body weight gain, food intake, and food efficiency were markedly decreased in rapamycin-treated rats.
- Histological analysis revealed reduced chondrocyte proliferation, disturbed chondrocyte maturation and hypertrophy, decreased cartilage resorption, and altered vascular invasion in the growth plates of rapamycin-treated animals.
Conclusions:
- Rapamycin severely impairs body growth and distorts growth plate structure and dynamics in young, fast-growing rats.
- The observed effects on growth plate cartilage formation and vascularization are significant.
- Caution is advised regarding the administration of rapamycin to children due to potential adverse effects on growth.
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
Inhibitors of Bacterial Protein Synthesis
Negative Regulator Molecules
Replicative Cell Senescence

